Synteract Acquires Pediatric CRO KinderPharm

Article

Applied Clinical Trials

Synteract, a CRO, has acquired KinderPharm, a pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. Together, Synteract and KinderPharm will deliver a single source model for preclinical and clinical development, along with the operational and logistical understanding required in working with children and their families.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.